Who are Clopidogrel, Prasugrel, Ticagrelor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Clopidogrel active metabolite, Clopidogrel reloading, Ticagrelor- Delayed Administration, Crushed ticagrelor, morphine,naloxone, Clopirin 2, Prasugrel based standard DAPT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clopidogrel-prasugrel-ticagrelor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Clopidogrel, Prasugrel, Ticagrelor — Competitive Intelligence Brief

Clopidogrel, Prasugrel, Ticagrelor (Clopidogrel, Prasugrel, Ticagrelor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist / Antiplatelet agent. Area: Cardiovascular.

marketed P2Y12 receptor antagonist / Antiplatelet agent P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Clopidogrel, Prasugrel, Ticagrelor (Clopidogrel, Prasugrel, Ticagrelor) — Centre hospitalier de l'Université de Montréal (CHUM). These are P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Clopidogrel, Prasugrel, Ticagrelor TARGET	Clopidogrel, Prasugrel, Ticagrelor	Centre hospitalier de l'Université de Montréal (CHUM)	marketed	P2Y12 receptor antagonist / Antiplatelet agent	P2Y12 receptor
Clopidogrel active metabolite	Clopidogrel active metabolite	University of Florida	marketed	P2Y12 receptor antagonist / Antiplatelet agent	P2Y12 receptor
Clopidogrel reloading	Clopidogrel reloading	University of Pecs	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Ticagrelor- Delayed Administration	Ticagrelor- Delayed Administration	Massachusetts General Hospital	marketed	P2Y12 platelet receptor antagonist	P2Y12 receptor
Crushed ticagrelor, morphine,naloxone	Crushed ticagrelor, morphine,naloxone	Collegium Medicum w Bydgoszczy	marketed	Antiplatelet agent + opioid + opioid antagonist combination	P2Y12 receptor (ticagrelor); mu opioid receptor (morphine); opioid receptors (naloxone antagonism)
Clopirin 2	Clopirin 2	Jeil Pharmaceutical Co., Ltd.	marketed	P2Y12 receptor antagonist / Antiplatelet agent	P2Y12 receptor
Prasugrel based standard DAPT	Prasugrel based standard DAPT	Research Maatschap Cardiologen Rotterdam Zuid	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist / Antiplatelet agent class)

Centre hospitalier de l'Université de Montréal (CHUM) · 1 drug in this class
Jeil Pharmaceutical Co., Ltd. · 1 drug in this class
University of Florida · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clopidogrel, Prasugrel, Ticagrelor — Competitive Intelligence Brief. https://druglandscape.com/ci/clopidogrel-prasugrel-ticagrelor. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab